GH Quote, Financials, Valuation and Earnings

Quest Diagnostics has a net margin of -56.28% compared to Guardant Health's net margin of 9.08%. Guardant Health's return on equity of -651% beat Quest Diagnostics's return on equity of 12.68%.

Guardant Health has a consensus price target of $42.30, signalling upside risk potential of 36.84%. On the other hand Quest Diagnostics has an analysts' consensus of $169.96 which suggests that it could grow by 10.78%. Given that Guardant Health has higher upside potential than Quest Diagnostics, analysts believe Guardant Health is more attractive than Quest Diagnostics.

Guardant Health has a beta of 1.255, which suggesting that the stock is 25.526% more volatile than S&P 500. In comparison Quest Diagnostics has a beta of 0.893, suggesting its less volatile than the S&P 500 by 10.74%.

Guardant Health has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Quest Diagnostics offers a yield of 1.93% to investors and pays a quarterly dividend of $0.75 per share. Guardant Health pays -- of its earnings as a dividend. Quest Diagnostics pays out 36.77% of its earnings as a dividend. Quest Diagnostics's payout ratio is sufficient to cover dividend payouts with earnings for the foreseeable future.

Guardant Health quarterly revenues are $191.5M, which are smaller than Quest Diagnostics quarterly revenues of $2.5B. Guardant Health's net income of -$107.8M is lower than Quest Diagnostics's net income of $226M. Notably, Guardant Health's price-to-earnings ratio is -- while Quest Diagnostics's PE ratio is 20.62x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Guardant Health is 5.54x versus 1.81x for Quest Diagnostics. Usually stocks with elevated PS ratios are considered overvalued.

Exact Sciences has a net margin of -56.28% compared to Guardant Health's net margin of -5.4%. Guardant Health's return on equity of -651% beat Exact Sciences's return on equity of -6.77%.

Guardant Health has a consensus price target of $42.30, signalling upside risk potential of 36.84%. On the other hand Exact Sciences has an analysts' consensus of $71.86 which suggests that it could grow by 23.66%. Given that Guardant Health has higher upside potential than Exact Sciences, analysts believe Guardant Health is more attractive than Exact Sciences.

Guardant Health has a beta of 1.255, which suggesting that the stock is 25.526% more volatile than S&P 500. In comparison Exact Sciences has a beta of 1.237, suggesting its more volatile than the S&P 500 by 23.719%.

Guardant Health has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Exact Sciences offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Guardant Health pays -- of its earnings as a dividend. Exact Sciences pays out -- of its earnings as a dividend.

Guardant Health quarterly revenues are $191.5M, which are smaller than Exact Sciences quarterly revenues of $708.7M. Guardant Health's net income of -$107.8M is lower than Exact Sciences's net income of -$38.2M. Notably, Guardant Health's price-to-earnings ratio is -- while Exact Sciences's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Guardant Health is 5.54x versus 3.95x for Exact Sciences. Usually stocks with elevated PS ratios are considered overvalued.

Natera has a net margin of -56.28% compared to Guardant Health's net margin of -7.18%. Guardant Health's return on equity of -651% beat Natera's return on equity of -26.45%.

Guardant Health has a consensus price target of $42.30, signalling upside risk potential of 36.84%. On the other hand Natera has an analysts' consensus of $167.90 which suggests that it could grow by 3.39%. Given that Guardant Health has higher upside potential than Natera, analysts believe Guardant Health is more attractive than Natera.

Guardant Health has a beta of 1.255, which suggesting that the stock is 25.526% more volatile than S&P 500. In comparison Natera has a beta of 1.628, suggesting its more volatile than the S&P 500 by 62.789%.

Guardant Health has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Natera offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Guardant Health pays -- of its earnings as a dividend. Natera pays out -- of its earnings as a dividend.

Guardant Health quarterly revenues are $191.5M, which are smaller than Natera quarterly revenues of $439.8M. Guardant Health's net income of -$107.8M is lower than Natera's net income of -$31.6M. Notably, Guardant Health's price-to-earnings ratio is -- while Natera's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Guardant Health is 5.54x versus 12.90x for Natera. Usually stocks with elevated PS ratios are considered overvalued.

Progyny has a net margin of -56.28% compared to Guardant Health's net margin of 3.64%. Guardant Health's return on equity of -651% beat Progyny's return on equity of 11.31%.

Guardant Health has a consensus price target of $42.30, signalling upside risk potential of 36.84%. On the other hand Progyny has an analysts' consensus of $30.22 which suggests that it could grow by 29.78%. Given that Guardant Health has higher upside potential than Progyny, analysts believe Guardant Health is more attractive than Progyny.

Guardant Health has a beta of 1.255, which suggesting that the stock is 25.526% more volatile than S&P 500. In comparison Progyny has a beta of 1.350, suggesting its more volatile than the S&P 500 by 34.952%.

Guardant Health has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Progyny offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Guardant Health pays -- of its earnings as a dividend. Progyny pays out -- of its earnings as a dividend.

Guardant Health quarterly revenues are $191.5M, which are smaller than Progyny quarterly revenues of $286.6M. Guardant Health's net income of -$107.8M is lower than Progyny's net income of $10.4M. Notably, Guardant Health's price-to-earnings ratio is -- while Progyny's PE ratio is 25.05x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Guardant Health is 5.54x versus 1.26x for Progyny. Usually stocks with elevated PS ratios are considered overvalued.